Table 2.
Summary of eight studies comparing the RECIST and EORTC criteria
| Study | Tumor type | No. of pts | Treatment | Comparison | Discordant rate, % | Details of discordance |
|---|---|---|---|---|---|---|
| RECIST→ EORTC | ||||||
| Monteil et al. (2009) [14] | Colorectal cancer | 25 | Palliative chemotherapy | RECIST 1.0 vs. EORTC | 80 (20/25) | 3 PR→2 CMR, 1 PMD |
| 17 SD→3 CMR, 13 PMR, 1 PMD | ||||||
| Thacker et al. (2012) [15] | Basal cell carcinoma | 14 | Targeted agent (vismodegib) | RECIST 1.0 vs. PER- CIST | 50 (7/14) | 2 PR→1 CMR, 1 SMD |
| 4 SD→4 PMR | ||||||
| 1 PD→1 SMD | ||||||
| Magnan et al. (2013) [16] | Desmoplastic small round cell tumor | 7 | Chemotherapy | RECIST 1.0 vs. EORTC | 71.4 (5/7) | 5 SD→5 PMR |
| Adkin et al. (2014) [17] | Head & neck cancer | 27 | Targeted therapy (cetuximab) | RECIST 1.0 vs. EORTC | 51.9 (14/27) | 14 SD→9 PMR, 5 PMD |
| Zukotynski et al. (2014) [18] | Malignant melanoma | 17 | Targeted therapy (imatinib) | RECIST 1.0 vs. EORTC | 29.4 (5/17) | 1 PR→1 SMD |
| 1 SD→1 PMD | ||||||
| 3 PD→1 PMR, 2 SMD | ||||||
| Puranik et al. (2015) [19]a | Non-small cell lung cancer | 31 | Targeted therapy (gefitinib) | RECIST 1.1 vs. EORTC | 9.7 (3/31) | 3 SD→3 PMR |
| Aras et al. (2016) [20] | Colorectal cancer | 20 | Chemotherapy | RECIST 1.1 vs. EORTC | 20 (12/60) | 4 PR→3 CMR, 1 SMD |
| Lung cancer | 16 | 8 SD→7 PMR, 1 PMD | ||||
| Stomach cancer | 12 | |||||
| Head & neck cancer | 6 | |||||
| Breast cancer | 6 | |||||
| Shang et al. (2016) [21] | Non-small cell lung cancer | 35 | Chemotherapy | RECIST 1.1 vs. EORTC | 57.1 (20/35) | 16 SD→12 PMR, 4 PMD |
| 4 PD→4 SMD | ||||||
| Summary | Lung cancer | 82 | RECIST vs. EORTC | 39.8 (86/216) | 10 PR→6 CMR, 3 SMD, 1 PMD | |
| Colorectal cancer | 45 | 68 SD→3 CMR, 53 PMR, 12 PMD | ||||
| Head & neck cancer | 33 | 8 PD→1 PMR, 7 SMD | ||||
| Malignant melanoma | 17 | |||||
| Basal cell carcinoma | 14 | |||||
| Stomach cancer | 12 | |||||
| Breast cancer | 6 | |||||
| Desmoplastic small round cell tumor | 7 |
RECIST, Response Evaluation Criteria in Solid Tumors; EORTC, European Organization Research and Treatment of Cancer; pts, patients; PR, partial response; CMR, complete metabolic response; PMD, progressive metabolic disease; SD, stable disease; PMR, partial metabolic response; SMD, stable metabolic disease; PD, progressive disease.
a
Because the RECIST 1.1 includes positron emission tomography for the detection of new lesions, two patients with new focal fluorodeoxyglucose avid marrow lesions were reclassified as having PD.